Table 4.

Polymorphisms in drug transporter genes affecting pharmacokinetics of anticancer drugs

Drugs	Gene	Mutations	dbSNP ID	ESP MAF		ExAC MAF	PK parameters
				African American	European American
Docetaxel	ABCB1	c.1236T>C	rs1128203	0.22	0.43	0.54	CL [1]
		c.3435T>C	rs1045642	0.23	0.48	0.50	CL [192]
Paclitaxel	ABCB1	c.1236T>C	rs1128203	0.22	0.43	0.54	AUC [193]
		c.2677T>A/G	rs2032582	nr	nr	0.54	AUC [193]
Etoposide	ABCB1	c.3435T>C	rs1045642	0.77	0.47	0.50	CL [194]
Doxorubicin	ABCB1	c.1236T>C	rs1128203	0.22	0.43	0.54	C max [106]
		c.2677T>A/G	rs2032582	nr	nr	0.54	CL [106]
	SLC22A16	c.146A>G	rs714368	0.36	0.22	0.25	AUC [195]
		c.312T>C	rs6907567	0.36	0.22	0.25	AUC [195]
Irinotecan	ABCB1	c.1236T>C	rs1128203	0.22	0.43	0.54	AUC, CL [110]
		Hap*2					CL [111]
Bicalutamide	ABCG2	c.421C>A	rs2231142	0.03	0.11	0.12	AUC, T max, C max, t 1/2, CL plasma concentrations [113]
Topotecan	ABCG2	c.421C>A	rs2231142	0.03	0.11	0.12	F [196]
Imatinib	ABCB1	c.1236T>C	rs1128203	0.22	0.43	0.54	C min, CL, F [116, 117]
		c.2677T>A/G	rs2032582	nr	nr	0.54	CL, F [117]
		c.3435T>C	rs1045642	0.23	0.48	0.50	CL, F [117]
		Hap*4					C min [116]
	ABCG2	c.421C>A	rs2231142	0.03	0.11	0.12	C min, CL [118, 119]
	SLC22A1	c.480C>G	rs683369	0.05	0.22	0.17	CL, C min [128]
Gefitinib	ABCG2	c.421C>A	rs2231142	0.03	0.11	0.12	C ss,min/C 1,min [123]
Sunitinib	ABCB1	c.2677T>A/G	rs2032582	nr	nr	0.54	CL [31]

The drug accumulation at the steady-state was assessed as the ratio of C _ss,min to C _1,min, where C _ss,min was the average pretreatment concentration on days 8, 15, 22 and 28, and C _1,min was the pretreatment concentration before the second dose

AUC area under the curve, ExAc Exome Aggregation Consortium, ESP Exome Sequencing Project, CL clearance, C _max maximum plasma concentration, C _min trough plasma concentration, C _ss,min /C _1,min, F oral bioavailability, MAF minor allele frequency, nr not reported, PK pharmacokinetic, T _max time to maximum plasma concentration, t _1/2 elimination half-life